In the latest session, Cytokinetics Inc (NASDAQ: CYTK) closed at $68.00 down -4.97% from its previous closing price of $71.56. On the day, 1516923 shares were traded.
Ratios:
For a deeper understanding of Cytokinetics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.12 and its Current Ratio is at 6.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, UBS on January 24, 2024, Downgraded its rating to Neutral and sets its target price to $92 from $61 previously.
On January 05, 2024, Morgan Stanley Downgraded its rating to Equal-Weight which previously was Overweight and also upped its target price recommendation from $60 to $90.
On November 09, 2023, Goldman started tracking the stock assigning a Buy rating and target price of $50.Goldman initiated its Buy rating on November 09, 2023, with a $50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Apr 09 ’24 when Malik Fady Ibraham sold 32,605 shares for $74.31 per share. The transaction valued at 2,422,918 led to the insider holds 138,567 shares of the business.
Malik Fady Ibraham sold 32,604 shares of CYTK for $2,202,606 on Mar 05 ’24. The EVP Research & Development now owns 138,973 shares after completing the transaction at $67.56 per share. On Feb 14 ’24, another insider, HENDERSON JOHN T, who serves as the Director of the company, sold 5,000 shares for $76.48 each. As a result, the insider received 382,400 and left with 42,632 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 944.41.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $25.98.
Shares Statistics:
A total of 101.64M shares are outstanding, with a floating share count of 100.94M. Insiders hold about 3.48% of the company’s shares, while institutions hold 108.23% stake in the company.
Earnings Estimates
There are Cytokinetics, Incorporated different market analysts currently analyzing its stock. The consensus estimate for the next quarter is $1.24, with high estimates of $3.01 and low estimates of $1.66.
Analysts are recommending an EPS of between $Healthcare and $Healthcare for the fiscal current year, implying an average EPS of $Healthcare.
